Breaking News

Novavax Names Corporate Development SVP

May 7, 2014

Andreasson brings extensive biopharma ops experience

Sven Andreasson has been appointed senior vice president, Corporate Development at Novavax, effective June 2, 2014. Mr. Andreasson will be responsible for identifying and evaluating new strategic opportunities leveraging the company's core strengths and growth initiatives.
 
Mr. Andreasson has extensive experience in biopharmaceutical operations, executive management and strategic development. He has served as executive officer of Isconova AB in Uppsala, Sweden, an international vaccine adjuvant company acquired by Novavax in 2013, currently operating as Novavax AB. Prior to this role, Mr. Andreasson served as chief executive officer of Beta-Cell NV in Brussels, Belgium and as chief executive officer of Active Biotech AB in Lund, Sweden. He also held roles senior roles at Pharmacia Corp.
 
"My first serious interactions with Sven occurred during our negotiations to acquire Isconova AB. I was immediately impressed with him as a pragmatic and thoughtful business professional. It became readily apparent to me that Novavax would benefit from his extensive vaccine and pharmaceutical industry experience and insight," said Stan Erck, president and chief executive officer of Novavax. "I am very excited to have someone with Sven's experience help me and the entire management team to evaluate organic and non-organic opportunities to build this business and increase shareholder value."
 

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important